Farther Finance Advisors
TRDA icon

Farther Finance Advisors’s Entrada Therapeutics TRDA Stock Holding History

Farther Finance Advisors’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.7K Buy
268
+125
+87% +$867 ﹤0.01% 5448
2026
Q2 		$1.05K Buy
143
+126
+741% +$1.21K ﹤0.01% 5364
2026
Q1 		$229 Buy
+17
New +$195 ﹤0.01% 5407

Other funds holding TRDA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

Farther Finance Advisors's TRDA Position: Q3 2026 in Review

Farther Finance Advisors increased its Entrada Therapeutics (TRDA) stake by 87% in Q3 2026, buying an estimated $867 and bringing the position to 268 shares worth $1.7K. The position accounts for ﹤0.01% of the portfolio, ranked #5448.

Farther Finance Advisors first reported a position in TRDA in Q1 2026 and has held it in 3 quarters since. 8 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • Farther Finance Advisors held 268 shares of Entrada Therapeutics worth $1.7K as of Q3 2026.
  • Farther Finance Advisors bought 125 Entrada Therapeutics shares in Q3 2026, an estimated $867.
  • Entrada Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5448 holding.
  • Farther Finance Advisors first reported a position in Entrada Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 8 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.